Literature DB >> 10688122

Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors.

J L Hornick1, J Sharifi, L A Khawli, P Hu, W G Bai, M M Alauddin, M M Mizokami, A L Epstein.   

Abstract

UNLABELLED: Recent studies in antibody catabolism have identified residues at the CH2-CH3 interface of the IgG heavy chain critical for serum persistence of immunoglobulins. Amino acid substitutions in the Fc region of murine IgG1 were shown to drastically accelerate antibody clearance in mice. Our laboratory has previously described a human-mouse chimeric TNT-3 (chTNT-3) monoclonal antibody directed against a universal nuclear antigen that has potential for the radioimmunotherapy of many solid tumors. In the current study, we engineered a chTNT-3 mutant containing a single amino acid substitution, to determine whether a more rapid clearance profile would make the antibody suitable for diagnostic imaging.
METHODS: A single amino acid substitution in the CH2 domain of the human gamma1 constant region was made by polymerase chain reaction mutagenesis. High-level expression was achieved using the Glutamine Synthetase Gene Amplification System, and the chTNT-3 mutant was purified by protein A affinity and ion-exchange chromatography. A radioimmunoassay was performed to examine antigen binding, and in vivo studies were undertaken to evaluate clearance and tumor targeting in human tumor xenograft models.
RESULTS: The chTNT-3 mutant retained the high affinity of chTNT-3, with a binding constant of 1.5 x 10(-9) mol/L. The mutant was eliminated rapidly from BALB/c mice, with a beta-phase half-life of 33.8 h, compared to 134.2 h for chTNT-3. Moreover, biodistribution studies in human colon tumor-bearing nude mice reflected this accelerated clearance. Tumor levels of the mutant were, respectively, 65%, 39%, and 36% of the tumor levels achieved with the parental chTNT-3 6, 12, and 24 h postinjection. The rapid clearance of the chTNT-3 mutant from the blood resulted in higher tumor-to-normal organ ratios for many normal tissues. Imaging of tumor-bearing mice with 99mTc-labeled chTNT-3 mutant demonstrated early visualization of tumors in 3 different solid tumor xenograft models.
CONCLUSION: The accelerated clearance produced by a single amino acid substitution in the Fc region of chTNT-3 leads to improved imaging in tumor-bearing mice. These studies suggest that a rapidly clearing antibody generated by this approach may be useful for the immunoscintigraphy of human tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688122

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Authors:  Vania Kenanova; Tove Olafsen; Desiree M Crow; Gobalakrishnan Sundaresan; Murugesan Subbarayan; Nora H Carter; David N Ikle; Paul J Yazaki; Arion F Chatziioannou; Sanjiv S Gambhir; Lawrence E Williams; John E Shively; David Colcher; Andrew A Raubitschek; Anna M Wu
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

2.  Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

Authors:  Tove Olafsen; Vania E Kenanova; Gobalakrishnan Sundaresan; Anne-Line Anderson; Desiree Crow; Paul J Yazaki; Lin Li; Michael F Press; Sanjiv S Gambhir; Lawrence E Williams; Jeffrey Y C Wong; Andrew A Raubitschek; John E Shively; Anna M Wu
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.

Authors:  Julie K Jang; Leslie A Khawli; David C Canter; Peisheng Hu; Tian H Zhu; Brian W Wu; Trevor E Angell; Zhongjun Li; Alan L Epstein
Journal:  Cancer Immunol Immunother       Date:  2016-03-09       Impact factor: 6.968

Review 4.  ImmunoPET: harnessing antibodies for imaging immune cells.

Authors:  Anna M Wu; Neeta Pandit-Taskar
Journal:  Mol Imaging Biol       Date:  2021-09-22       Impact factor: 3.488

5.  Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.

Authors:  Ingrid J G Burvenich; William Farrugia; Fook T Lee; Bruno Catimel; Zhanqi Liu; Dahna Makris; Diana Cao; Graeme J O'Keefe; Martin W Brechbiel; Dylan King; Violeta Spirkoska; Laura C Allan; Paul A Ramsland; Andrew M Scott
Journal:  MAbs       Date:  2016-03-30       Impact factor: 5.857

6.  Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies.

Authors:  Julie K Jang; John Chretin; David Bruyette; Peisheng Hu; Alan L Epstein
Journal:  J Cancer Sci Ther       Date:  2015-05-30

7.  Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers.

Authors:  Ingrid J G Burvenich; Fook-Thean Lee; Graeme J O'Keefe; Dahna Makris; Diana Cao; Sylvia Gong; Angela Rigopoulos; Laura C Allan; Martin W Brechbiel; Zhanqi Liu; Paul A Ramsland; Andrew M Scott
Journal:  EJNMMI Res       Date:  2016-03-17       Impact factor: 3.138

8.  Updated developments on molecular imaging and therapeutic strategies directed against necrosis.

Authors:  Dongjian Zhang; Meng Gao; Qiaomei Jin; Yicheng Ni; Jian Zhang
Journal:  Acta Pharm Sin B       Date:  2019-02-13       Impact factor: 11.413

9.  Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis.

Authors:  Claire Harris; Weichen Xu; Luigi Grassi; Chunlei Wang; Abigail Markle; Colin Hardman; Richard Stevens; Guillermo Miro-Quesada; Diane Hatton; Jihong Wang
Journal:  MAbs       Date:  2019-10-01       Impact factor: 5.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.